Compound class:
Synthetic organic
Comment: The chemical structure for glovadalen was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a dopamine D1 receptor positive allosteric modulator (PAM). It is claimed in UCB Biopharma's patent WO2021001288A1 [1]. Exploration of UCB's declared pipeline suggests that glovadalen may be their clinical lead UCB0022, that is being developed for Parkinson's disease [2]. We will update this entry when the structure for UCB0022 and/or glovadalen is published.
|
|
References |
1. Ates A, Skolc D. (2021)
A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator. Patent number: WO2021001288A1. Assignee: UCB Biopharma SRL. Priority date: 29/06/2020. Publication date: 07/01/2021. |
2. McFarthing K, Buff S, Rafaloff G, Fiske B, Mursaleen L, Fuest R, Wyse RK, Stott SRW. (2023)
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update. J Parkinsons Dis, 13 (4): 427-439. [PMID:37302040] |